Prenatal serotonin reuptake inhibitor antidepressant exposure, SLC6A4 genetic variations, and cortisol activity in 6-year-old children of depressed mothers: A cohort study

Dev Psychobiol. 2023 Nov;65(7):e22425. doi: 10.1002/dev.22425.

Abstract

Prenatal exposure to maternal depression and serotonin reuptake inhibitor (SRI) antidepressants both affect the development of the hypothalamic-pituitary-adrenal (HPA) system, possibly via the neurotransmitter serotonin (5HT). In a community cohort, we investigated the impact of two factors that shape prenatal 5HT signaling (prenatal SRI [pSRI] exposure and child SLC6A4 genotype) on HPA activity at age 6 years. Generalized estimating equation (GEE) models were used to study associations between cortisol reactivity, pSRI exposure, and child SLC6A4 genotype, controlling for maternal depression, child age, and sex (48 pSRI exposed, 74 nonexposed). Salivary cortisol levels were obtained at five time points during a laboratory stress challenge: arrival at the laboratory, following two sequential developmental assessments, and then 20 and 40 min following the onset of a stress-inducing cognitive/social task. Cortisol decreased from arrival across both developmental assessments, and then increased across both time points following the stress challenge in both groups. pSRI-exposed children had lower cortisol levels across all time points. In a separate GEE model, we observed a lower cortisol stress response among children with LG /S alleles compared with children with La/La alleles, and this was particularly evident among children of mothers reporting greater third trimester depressed mood. Our findings suggest that pSRI exposure and a genetic factor associated with modulating 5HT signaling shaped HPA reactivity to a laboratory stress challenge at school age.

Keywords: SLC6A4 genotype; cortisol; depression; pregnancy; serotonin reuptake inhibitors; stress response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Child
  • Cohort Studies
  • Depression* / drug therapy
  • Depression* / metabolism
  • Depression* / physiopathology
  • Female
  • Genetic Variation
  • Humans
  • Hydrocortisone* / analysis
  • Hydrocortisone* / metabolism
  • Hypothalamo-Hypophyseal System / drug effects
  • Hypothalamo-Hypophyseal System / embryology
  • Hypothalamo-Hypophyseal System / physiopathology
  • Pituitary-Adrenal System / drug effects
  • Pituitary-Adrenal System / embryology
  • Pituitary-Adrenal System / physiopathology
  • Pregnancy
  • Pregnancy Complications* / chemically induced
  • Pregnancy Complications* / genetics
  • Pregnancy Complications* / metabolism
  • Pregnancy Complications* / psychology
  • Prenatal Exposure Delayed Effects* / chemically induced
  • Prenatal Exposure Delayed Effects* / genetics
  • Prenatal Exposure Delayed Effects* / metabolism
  • Prenatal Exposure Delayed Effects* / psychology
  • Saliva / chemistry
  • Selective Serotonin Reuptake Inhibitors* / pharmacology
  • Selective Serotonin Reuptake Inhibitors* / therapeutic use
  • Serotonin / analysis
  • Serotonin / metabolism
  • Serotonin Plasma Membrane Transport Proteins / genetics
  • Serotonin Plasma Membrane Transport Proteins / metabolism
  • Stress, Psychological / genetics
  • Stress, Psychological / metabolism
  • Stress, Psychological / physiopathology

Substances

  • Antidepressive Agents
  • Hydrocortisone
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin Plasma Membrane Transport Proteins
  • SLC6A4 protein, human
  • Serotonin

Grants and funding